New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 2, 2013
07:56 EDTABBV, ABTAbbott completes separation of research-based pharmaceutical business
Abbott (ABT) announced it has completed the separation of its research-based pharmaceuticals business, which became AbbVie (ABBV), a new independent biopharmaceutical company. AbbVie will begin trading independently on the New York Stock Exchange today under the symbol "ABBV."
News For ABT;ABBV From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 30, 2015
14:07 EDTABBVProPublica says Medicare spent $4.5B on hepatitis C treatments last year
Subscribe for More Information
10:24 EDTABTMylan volatility up after filing to sell 35M shares for Abbott Laboratories
Subscribe for More Information
09:27 EDTABTOn The Fly: Pre-market Movers
Subscribe for More Information
09:15 EDTABTTeva does not rule out bigger deal if opportunity arises
Subscribe for More Information
09:02 EDTABTMylan slips amid Abbott share sale, Teva deal for Auspex
Subscribe for More Information
March 27, 2015
07:07 EDTABBVBiogen, AbbVie say EMA validates MAA for Zinbryta for treatment of MS
Biogen (BIIB) and AbbVie (ABBV) announced that the European Medicines Agency has validated the companies’ Marketing Authorisation Application for ZINBRYTA for the treatment of relapsing forms of multiple sclerosis in the European Union. Validation confirms that the submission is complete and signifies the initiation of the review process by the EMA’s Committee for Medicinal Products for Human Use. The MAA included results from two clinical trials, DECIDE and SELECT, in which ZINBRYTA 150 mg was administered subcutaneously every four weeks in people with relapsing-remitting MS. Biogen and AbbVie are jointly developing ZINBRYTA.
March 23, 2015
09:03 EDTABBVLeerink analysts hold a meeting with a conference call hookup
Subscribe for More Information
09:03 EDTABTFiserv says Abbott employee credit union expands partnership
Subscribe for More Information
07:17 EDTABBVAmerican Academy of Dermatology to hold annual meeting
73rd Annual Meeting of AAD is being held in San Francisco on March 20-24.
March 20, 2015
07:41 EDTABBVAmerican Academy of Dermatology to hold annual meeting
Subscribe for More Information
March 19, 2015
08:47 EDTABBVAbbVie and C2N sign worlwide license agreement for Alzheimer's Disease therapy
AbbVie has entered into an exclusive worldwide license agreement with C2N Diagnostics, a privately held protein diagnostic and therapeutic discovery company, to develop and commercialize a portfolio of anti-tau antibodies for the treatment of Alzheimer's Disease and other neurological disorders. Financial terms of the collaboration were not disclosed.
07:56 EDTABBVAbbVie plans $30M expansion at plant in Puerto Rico, AP reports
AbbVie is planning to expand one of its facilities in Barceloneta, Puerto Rico, The Associated Press reports. The $30M expansion is slated for a plant that manufactures products related to immunology, virology and metabolic disorders. Reference Link
March 17, 2015
08:03 EDTABBVAbbVie to present data from 22 HUMIRA abstracts at AAD
Subscribe for More Information
06:31 EDTABBVStudies find Gilead's hepatitis C drugs cost effective, Reuters says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use